Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 9/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | TPH1 | P17752 | 2/20 | 0.43 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14089886 | 0.84 | S1PR1 (0.59) | S1PR1HDAC1HDAC8HDAC2TPH1 | |
| SCHEMBL14089862 | 0.83 | HDAC1 (0.60) | S1PR1HDAC1HDAC8HDAC2HDAC4 | |
| SCHEMBL14089952 | 0.82 | S1PR1 (0.57) | S1PR1HDAC1HDAC8HDAC2TPH1 | |
| SCHEMBL14089852 | 0.82 | S1PR1 (0.58) | S1PR1HDAC1HDAC8HDAC2S1PR4 | |
| SCHEMBL14089913 | 0.80 | S1PR1 (0.56) | S1PR1HDAC1HDAC8S1PR4S1PR5 | |
| SCHEMBL14089912 | 0.80 | S1PR1 (0.56) | S1PR1HDAC1HDAC8HDAC2S1PR4 | |
| SCHEMBL14089874 | 0.79 | S1PR1 (0.59) | S1PR1HDAC1HDAC8S1PR3HDAC4 | |
| SCHEMBL14089843 | 0.78 | S1PR1 (0.58) | S1PR1TPH1S1PR4S1PR5S1PR3 | |
| SCHEMBL14089879 | 0.78 | S1PR1 (0.54) | S1PR1HDAC1HDAC8HDAC2TPH1 | |
| SCHEMBL14089847 | 0.77 | S1PR1 (0.58) | S1PR1S1PR5S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200535-A1 | sphingosine 1-phosphate-1/EDG-1 receptor agonists; autoimmune diseases; immunosuppressants by inducing lymphocyte sequestration in secondary lymphoid tissues; 4-aminocyclopentane-2-encarboxylic acid hydrochloric acid salt | S1PR1, S1PR2, S1PR4 | S1PR1 1/4885HDAC1 1133/4885HDAC8 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.